Pancreatic Adenocarcinoma

Upregulation of STEAP3 suppresses ferroptosis by increasing glutathione levels and reducing lipid peroxidation, ultimately promoting tumor proliferation and gemcitabine resistance. Our study identifies the USP10-IGF2BP3-STEAP3 axis as a critical mechanism underlying chemoresistance in pancreatic cancer, suggesting that targeting USP10 may offer a promising therapeutic strategy for overcoming gemcitabine resistance.

Our findings suggest the existence of a Vav1/PDX1/miR-375/Akt axis as part of the complex network orchestrating the generation of functional β cells. These insights indicate that strategies aimed at specifically modulating Vav1 levels may positively impact the generation of IPCs in vitro and, ultimately, β cell replacement therapy for T1D.

The random survival forest model demonstrated superior predictive performance, achieving a concordance index of 0.634 and time-dependent receiver operating characteristic area under the curve values of 0.973, 0.978, and 0.996 at 1, 2, and 3 years, respectively. In conclusion, this study identifies 12 critical drug resistance genes in PAAD and highlights the associated immune differences in patient risk, paving the way for targeted immunotherapy research to improve therapeutic strategies against this formidable disease.

At the time of drafting this report, the patient had achieved 8 months of PFS. This case suggests that dose-adjusted dabrafenib combined with trametinib might be a potentially effective treatment strategy for elderly patients with advanced pancreatic adenocarcinoma harboring BRAF V600E mutations.

P=N/A, N=199, Active, not recruiting, Massachusetts General Hospital | Phase classification: P2 --> P=N/A | Trial completion date: Nov 2023 --> Dec 2027 | Trial primary completion date: Nov 2023 --> Aug 2025 | Recruiting --> Active, not recruiting

PLXDC2 is a potential biomarker of PDAC diagnosis. Targeting the PLXDC2-cortactin interaction may offer a novel therapeutic strategy.

P=N/A, N=15, Recruiting, Alpha Tau Medical LTD. | Trial completion date: Nov 2025 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2026

P1/2, N=30, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2024 --> Jan 2026

This pan-cancer study elucidates the pivotal role of ENTPD6 in tumor progression and establishes its potential as a therapeutic target for immunotherapeutic approaches in specific malignancies.

Collectively, our study not only provides a powerful prognostic tool but also identifies a promising multi-target natural compound, offering a novel strategy to overcome chemoresistance in PAAD.

P1, N=55, Active, not recruiting, University of Southern California | Trial completion date: Dec 2025 --> Jul 2026

P2, N=9, Terminated, Ludwig-Maximilians - University of Munich | N=92 --> 9 | Trial completion date: May 2024 --> Nov 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Nov 2025; Low accrual, close out in November 2025